Human SCN11A Stable Cell Line - HEK293

SCN11A, also known as Nav1.9, is a voltage-gated sodium channel alpha subunit encoded by the SCN11A gene in humans. It belongs to the family of sodium channel proteins responsible for the initiation and propagation of action potentials in excitable cells. Unlike other sodium channels, Nav1.9 is predominantly expressed in nociceptive neurons within the dorsal root ganglia and trigeminal ganglia, where it plays a key role in setting the resting membrane potential and amplifying subthreshold depolarizations. Mutations in SCN11A have been linked to hereditary sensory and autonomic neuropathy type VII and familial episodic pain syndrome type 3, underscoring its importance in pain signaling. The Human SCN11A Stable Cell Line - HEK293 is generated by transfecting the human SCN11A gene into HEK293 cells, followed by stable selection to ensure consistent and long-term expression of the functional Nav1.9 channel on the cell surface. This engineered cell line provides a reliable in vitro platform for studying the biophysical properties, pharmacological modulation, and disease-associated variants of the Nav1.9 channel in a controlled and reproducible cellular background.

This stable cell line serves as a valuable tool for a range of research applications. It is particularly useful in electrophysiological studies using patch-clamp techniques to characterize the activation, inactivation, and conductance properties of Nav1.9, as well as its responses to various modulators. Researchers also employ this cell line in high-throughput screening campaigns to identify novel small-molecule inhibitors or activators targeting Nav1.9, which is considered a promising therapeutic target for chronic pain conditions, including inflammatory pain and neuropathic pain. Additionally, the line can be used to evaluate the functional impact of clinically relevant SCN11A mutations, helping to bridge the gap between genetic findings and molecular mechanisms. In drug discovery workflows, the Human SCN11A Stable Cell Line - HEK293 supports safety pharmacology assessments by enabling the evaluation of off-target effects on Nav1.9 during early-stage compound development. The stable nature of the expression system ensures assay consistency across experiments, making it suitable for both basic research and translational studies aimed at understanding sodium channel biology and developing next-generation pain therapeutics.